Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?

Roche's latest breakthrough could be a game changer, but it's still too early to say. That's just what happened after an announcement by Roche Holding (RHHBY 3.03%) on July 16. Shares of Novo Nordisk (NVO -0.88%), Eli Lilly (LLY -2.02%), Structure Therapeutics, Altimmune, and Viking Therapeutics all took a hit. Biotechs with clinical-stage weight loss candidates, specifically Viking and Altimmune, fell by nearly 13%, with larger players dropping by more than 4% even while the market was mostly flat. The mar ...